pipeline-prospector-insert
X

Find Clinical Drug Pipeline Developments & Deals for Bortezomib

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Selinexor,Bortezomib,Dexamethasone

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 28, 2020

            Details:

            Combination of once-weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) and Dexamethasone (svd) prolonged median progression-free survival by 47% compared to standard twice-weekly velcade® plus dexamethasone (Vd).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Belantamab mafodotin,Bortezomib,Dexamethasone

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 27, 2020

            Details:

            13-month update on the DREAMM-2 study shows median overall survival of 14.9 months and median duration of response of 11 months with single-agent belantamab mafodotin 2.5 mg/kg dose.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Selinexor,Bortezomib,Dexamethasone

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 20, 2020

            Details:

            sNDA is backed by the top-line results from the pivotal Phase 3 BOSTON study evaluating the combination of XPOVIO (selinexor), once-weekly Velcade® (bortezomib) and low-dose dexamethasone as a second line treatment for patients with relapsed or refractory multiple myeloma.